Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ORIC is a clinical stage oncology company with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ORIC, as reflected in its Form 8-K filings.
Investors can review current reports on Form 8-K in which ORIC discloses material events such as quarterly financial results, clinical program updates, and corporate presentations. For example, the company has filed 8-Ks to announce financial results for quarters ended June 30 and September 30, 2025, to furnish updated ORIC-944 corporate presentation slides, and to provide an enozertinib (ORIC-114) program update summarizing Phase 1b trial data. Certain 8-Ks also describe strategic pipeline prioritization measures, including workforce reductions and a focus on lead programs ORIC-944 and enozertinib.
ORIC’s filings include details on its status as an emerging growth company, the registration of its common stock on The Nasdaq Global Select Market, and exhibits such as press releases and investor presentations. These documents also contain cautionary notes regarding forward-looking statements and refer readers to risk factor discussions in periodic reports like Form 10-Q.
On Stock Titan, ORIC’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy filings by highlighting items such as reported financial results, clinical milestones, strategic changes, and capital raising activities. Users can quickly see what each 8-K covers, identify attached exhibits such as presentations, and understand how new disclosures may relate to ORIC’s oncology pipeline and Nasdaq-listed equity.
In addition to 8-Ks, this page links to ORIC’s other SEC documents available on EDGAR, allowing investors to follow the company’s regulatory history, governance disclosures, and risk factor updates as its clinical programs advance.
The SEC has declared Oric Pharmaceuticals' Form S-3 registration statement effective as of June 20, 2025, at 4:00 P.M. The registration statement was filed under file number 333-287949.
Form S-3 is a shelf registration that allows publicly traded companies to register securities for future public offerings. This effectiveness notice indicates that Oric Pharmaceuticals has met SEC requirements and can now proceed with their planned securities offering(s).
This regulatory development suggests that Oric Pharmaceuticals may be positioning itself for potential future capital raising activities, which could include offerings of common stock, preferred stock, debt securities, warrants, or other securities as specified in their registration statement.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
